Parkinson's Disease
Conditions
Interventions
The placebo group:The placebo acupuncture
research group:acupuncture
Sponsors
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
30 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Patients with Parkinson's disease who meet the diagnostic criteria and have a Hoehn-Yahr stage of =3; (2) Male or female aged 30~75 years; (3) Confirmed to have motor disorders by the Parkinson's Disease Comprehensive Rating Scale (MDS-UPDRS) with one or more of the following mild motor symptoms including but not limited to: resting tremor (such as involuntary trembling of the fingers) muscle rigidity (such as a feeling of stiffness in the arms or legs) bradykinesia (such as slowed movements reduced stride when walking) ; (4) Normal mental cognitive and conscious states willing to sign the informed consent form agree to cooperate with the treatment methods and course of this study and willing to complete the rating scales; (5) Able to tolerate acupuncture treatment; (6) Stable use of anti-Parkinson's medication within 30 days.
Exclusion criteria
Exclusion criteria: (1) Motor disorders or Parkinsons syndrome caused by other diseases; (2) Those who have previously received deep brain stimulation (DBS) or other surgical treatments related to Parkinsons disease; (3) Patients with concurrent neurological diseases that may affect motor symptoms; (4) Individuals currently using antipsychotic or antidepressant medications that may impact the analysis of study data; (5) Patients who do not meet the inclusion criteria regarding age disease duration and severity of symptoms; (6) Those with a history of epilepsy; (7) Patients with significant organ dysfunction; (8) Individuals with chronic wasting diseases or hematopoietic system diseases; (9) Patients with severe cognitive impairment or psychiatric symptoms who are unable to cooperate with the study requirements; (10) Individuals who are afraid of acupuncture or are currently participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Uni?ed Parkinsons disease rating scale-?; | — |
Secondary
| Measure | Time frame |
|---|---|
| Activities of Daily Living Scale (ADL);levodopa equivalent daily dose (LEDD);Parkinson's Disease Questionaire-39;Proteomics;ReadyGo Motor Function Quantitative Evaluation System: PD Gait Analysis;Metabolomics;Hoehn-Yahr Staging Scale; | — |
Countries
China
Contacts
Public ContactDong Zhengni
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Outcome results
None listed